*Centre Hospitalier Universitaire de l'Hôpital Nord, Marseille, France;
†Vitreous Retina Macula Consultants of New York, New York, New York;
‡Department of Ophthalmology, NYU Langone School of Medicine, New York, New York;
§Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland;
¶Department of Ophthalmology, San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy;
**Department of Ophthalmology, Hospital das Clínicas da FMUSP, São Paulo, Brazil;
††Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan; and
‡‡Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Reprint requests: K. Bailey Freund, MD, Vitreous Retina Macula Consultants of New York, 460 Park Avenue, New York, NY 10022; e-mail: [email protected]
Supported by The Macula Foundation, Inc, New York, NY.
K. B. Freund is a consultant for Heidelberg Engineering, Zeiss, Genentech, Bayer, Novartis, and Allergan; he receives research support from Genentech/Roche. C. A. Curcio receives research support from Heidelberg Engineering and owns stock of MacRegen. C. G. Besirli is a consultant for iRenix Medical and Janssen and receives equity (iRenix Medical) and royalty (iRenix Medical, ONL Therapeutics), clinical trial support (MeiraGTx, Spark Therapeutics, 4DMT, Regeneron, Novartis), and research support (NIH, The E. Matilda Ziegler Foundation for the Blind, International Retinal Research Foundation). The remaining authors have no financial/conflicting interests to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).
